Vera Therapeutics reports 76% lower kidney-progression risk for TRUTAKNA in final ORIGIN 3 analysis

This is a genuine, atomic clinical-trial result with explicit efficacy and safety evidence, not price action or commentary. Vera reported that the final ORIGIN 3 analysis of 428 participants met all prespecified endpoints, including a 76% reduction in composite kidney-disease progression events versus placebo and statistically significant eGFR improvements. The result is materially forward-looking because it can affect TRUTAKNA’s regulatory and commercial outlook and the competitive positioning of other IgA nephropathy therapies. Earlier proteinuria results and the expected final analysis were known, so the surprise is meaningful but not maximal. The announcement timestamp is used as the best estimate because the exact underlying trial-result time is not separately stated. VERA and directly competing IgA nephropathy drug developers are approved stakeholders; distributors, payers, and more indirect pipeline exposures are excluded because the evidence does not establish a direct effect on their future expectations.